Infographic | HCPs must deal with communication breakdown

Infographic | HCPs must deal with communication breakdown

Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.

How Aubagio became the most switched-to oral MS drug

How Aubagio became the most switched-to oral MS drug

Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force

Why haven't biosimilars gained ground in the U.S.?

Why haven't biosimilars gained ground in the U.S.?

Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?

Merck to axe 1,800 sales positions, form new chronic-care sales team

Merck to axe 1,800 sales positions, form new chronic-care sales team

The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.

Up to 20% of pharma brands moving digital media spend to point-of-care

Up to 20% of pharma brands moving digital media spend to point-of-care

Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.

Drugmakers turn to social — not TV — to market drugs to women

Drugmakers turn to social — not TV — to market drugs to women

Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.

Top 25 women's health brands, based on U.S. sales in 2016

Top 25 women's health brands, based on U.S. sales in 2016

Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.

Infographic | The leaders of the global hepatitis-C market

Infographic | The leaders of the global hepatitis-C market

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.